Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-β2 and FLT3 in hematopoiesis

Blood

Volumn 118, Issue 23, 2011, Pages 6078-6086

  Avagyan, Serine ^a   Aguilo, Francesca ^b   Kamezaki, Kenjiro ^b   Snoeck, Hans Willem ^b  

^a NewYork Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLUOROURACIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POSITIVE REGULATORY DOMAIN CONTAINING DOMAIN CONTAINING 16; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRESS; CONTROLLED STUDY; GENE FUNCTION; GENETIC VARIABILITY; HEMATOPOIESIS; INBRED STRAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS MAPPING; QUANTITATIVE TRAIT MAPPING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

EID: 82955207702     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365080     Document Type: Article

References (50)

1. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132(4): 631-644. (Pubitemid 351260057)
2. Metcalf D. On hematopoietic stem cell fate. Immunity. 2007;26(6):669-673. (Pubitemid 46908963)
3. Van Zant G, Holland BP, Eldridge PW, Chen JJ. Genotype-restricted growth and aging patterns in hematopoietic stem cell populations of allophenic mice. J Exp Med. 1990;171(5):1547-1565. (Pubitemid 20167550)
4. Muller-Sieberg CE, Riblet R. Genetic control of the frequency of hematopoietic stem cells in mice: mapping of a candidate locus to chromosome 1. J Exp Med. 1996;183(3):1141-1150. (Pubitemid 26113977)
5. de Haan G, Van Zant G. Intrinsic and extrinsic control of hematopoietic stem cell numbers: mapping of a stem cell gene. J Exp Med. 1997;186(4): 529-536. (Pubitemid 27360797)
6. De Haan G, Van Zant G. Genetic analysis of hemopoietic cell cycling in mice suggests its involvement in organismal life span. FASEB J. 1999;13(6):707-713. (Pubitemid 29156402)
7. Chen J, Astle CM, Muller-Sieburg CE, Harrison DE. Primitive hematopoietic stem cell function in vivo is uniquely high in the CXB-12 mouse strain. Blood. 2000;96(13):4124-4131.
8. Hasegawa M, Baldwin TM, Metcalf D, Foote SJ. Progenitor cell mobilization by granulocyte colony-stimulating factor controlled by loci on chromosomes 2 and 11. Blood. 2000;95(5):1872- 1874.
9. Morrison SJ, Qian D, Jerabek L, et al. A genetic determinant that specifically regulates the frequency of hematopoietic stem cells. J Immunol. 2002;168(2):635-642. (Pubitemid 34049563)
10. Henckaerts E, Geiger H, Langer JC, Rebollo P, Van Zant G, Snoeck HW. Genetically determined variation in the number of phenotypically defined hematopoietic progenitor and stem cells and in their response to early-acting cytokines. Blood. 2002;99(1):3947-3954. (Pubitemid 35332033)
11. Geiger H, Rennebeck G, Van Zant G. Regulation of hematopoietic stem cell aging in vivo by a distinct genetic element. Proc Natl Acad Sci U S A. 2005(14):102:5102-5107.
12. Bystrykh L, Weersing E, Dontje B, et al. Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet. 2005;37(3):225-232. (Pubitemid 41716249)
13. Liang Y, Jansen M, Aronow B, Geiger H, Van Zant G. The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet. 2007;39(2):178-188. (Pubitemid 46184348)
14. Van Zant G, Liang Y. Natural genetic diversity as a means to uncover stem cell regulatory pathways. Ann N Y Acad Sci. 2009;1176:170-177.
15. Mackay TF, Stone EA, Ayroles JF. The genetics of quantitative traits: challenges and prospects. Nat Rev Genet. 2009;10(8):565-577.
16. Peters LL, Robledo RF, Bult CJ, Churchill GA, Paigen BJ, Svenson KL. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev Genet. 2007;8(1):58-69. (Pubitemid 46006050)
17. Langer JL, Henckaerts E, Orenstein J, Snoeck HW. Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of hematopoietic progenitor and stem cells. J Exp Med. 2004;199(1):5-14. (Pubitemid 38076473)
18. Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene. 2005;24(37): 5676-5692. (Pubitemid 43086128)
19. Langer JC, Henckaerts E, Orenstein J, Snoeck HW. The positive regulatory effect of transforming growth factor-beta2 on primitive progenitor and stem cells is dependent on age, genetic background, and serum factors. J Immunol. 2004;176(4):2486-2493. (Pubitemid 39063106)
20. Avagyan S, Glouchkova L, Choi J, Snoeck HW. A quantitative trait locus on chromosome 4 affects cycling of hematopoietic stem and progenitors cells through regulation of TGF-beta2 responsiveness. J Immunol. 2008;181(9):5904- 5911.
21. Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood. 2011;117(19):5057-5066.
22. Chuikov S, Levi BP, Smith ML, Morrison SJ. Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nat Cell Biol. 2010;12(10):999-1006.
23. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289-312.
24. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development. 1997;124(13):2659-2670. (Pubitemid 27341765)
25. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100(26):15712-15717. (Pubitemid 38021055)
26. Kuhn R, Schwen F, Aguet M, et al., Inducible gene targeting in mice. Science. 1995;269(5229): 1427-1429.
27. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3(1):147-161.
28. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62(1):65- 74.
29. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109-1121. (Pubitemid 40884400)
30. Buza-Vidas N, Cheng M, Duarte S, et al. FLT3 receptor and ligand are dispensable for maintenance and posttransplantation expansion of mouse hematopoietic stem cells. Blood. 2009; 113(15):3453-3460.
31. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665. (Pubitemid 37328820)
32. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184(5):1953-1962. (Pubitemid 26404485)
33. Brasel K, McKenna HJ, Morrissey PJ, et al. Hematologic effects of flt3 ligand in vivo in mice. Blood. 1996;88(6):2004-2012. (Pubitemid 26307902)
34. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. 2007;8(11): 1207-1216. (Pubitemid 350011759)
35. Flint J, Valdar W, Shifman S, Mott R. Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet. 2005;6(4):271-286. (Pubitemid 40469047)
36. Darvasi A. Interval-specific congenic strains (ISCS): an experimental design for mapping a QTL into a 1-centimorgan interval. Mamm Genome. 1997;8(3):163-167. (Pubitemid 28060692)
37. Mochizuki N, Shimizu S, Nagasawa T, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 2000;96(9):3209-3214.
38. Sakai I, Tamura T, Narumi H, et al. Novel RUNX1- PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer. 2005;44(3):265- 270.
39. Shing DC, Trubia M, Marchesi F, et al. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest. 2007;117(12):3696-3707. (Pubitemid 350224081)
40. Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008; 454(7207):961-967.
41. Seimandi M, Lemaire G, Pillon A, et al. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem. 2005; 344(1):8-15. (Pubitemid 41569372)
42. Benko I, Djazayeri K, Abrahám C, Zsuga J, Szilvássy Z. Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. Eur J Pharmacol. 2003;477(2):179-182. (Pubitemid 38373535)
43. Kumar R, Avagyan S, Snoeck HW. A quantitative trait locus on chr.4 regulates thymic involution. J Gerontol A: Biol Sci. 2010;65(6):620-625.
44. Kumar R, Langer JC, Snoeck HW. Transforming growth factor-beta2 is involved in quantitative genetic variation in thymic involution. Blood. 2006; 107(5):1974-1979. (Pubitemid 43289380)
45. Youm YH, Yang H, Amin R, Smith SR, Leff T, Dixit VD. Thiazolidinedione treatment and constitutive- PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution. Aging Cell. 2010;9(4):478-489.
46. Adolfsson J, Borge OJ, Bryder D, et al. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity. 2001;15(4):659-669. (Pubitemid 33016450)
47. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001;98(25):14541-14546. (Pubitemid 33121428)
48. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 2008; 180:7358-7367.
49. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood. 2003;102(3):881-886. (Pubitemid 36917779)
50. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88:4493-4499. (Pubitemid 26419132)